Natco Pharma Limited, a prominent player in the Indian pharmaceutical industry, has announced the upcoming superannuation of one of its key executives. Dr. Santhan Gopalakrishnan Vaidyanathan, currently serving as the Senior Vice President of ARD (Active Research and Development), is set to retire from the company.

Retirement Details

According to the company's disclosure under SEBI regulations, Dr. Vaidyanathan will superannuate from his role effective from the closure of business hours on September 30, 2025. This information was communicated to both the BSE Limited and the National Stock Exchange of India Ltd.

Company Disclosure

Natco Pharma Limited made this announcement in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided the following details as required by the regulatory guidelines:

Impact on NATCO Pharma

Dr. Vaidyanathan's departure marks the end of his tenure as a senior executive in Natco Pharma's Active Research and Development division. While the company has not provided specific details about Dr. Vaidyanathan's contributions or a succession plan, his role as Senior Vice President - ARD suggests he has been a key figure in the company's research and development efforts.

Natco Pharma, known for its strong presence in the pharmaceutical sector, particularly in oncology and hepatitis C treatments, will likely plan for a smooth transition as the date of Dr. Vaidyanathan's superannuation approaches.

The announcement of this high-level change comes as part of Natco Pharma's commitment to transparency and adherence to regulatory requirements. As the pharmaceutical landscape continues to evolve, the company's ability to maintain strong leadership in its research and development arm will be crucial for its future innovations and market position.

Natco Pharma , a prominent player in the pharmaceutical industry, has taken a significant step towards restructuring its business operations. The company's board of directors has given in-principle approval to evaluate the demerger of its agro business into a separate entity, a move aimed at unlocking value and fostering long-term growth.

Key Highlights

• Natco Pharma's board approves assessment of agro business spin-off
• The decision aims to boost core pharma value and support long-term growth
• Proposed reorganization may result in Natco retaining a minority stake in the new entity

Strategic Rationale

The management of Natco Pharma believes that this strategic move will offer several benefits:

1. Value Unlocking: The demerger is expected to unlock the value of the core pharmaceutical business, potentially leading to better market valuation.

2. Enhanced Focus: By separating the agro business, both entities can have dedicated management teams, allowing for more focused operational strategies.

3. Operational Flexibility: The split will provide greater operational flexibility for both the pharmaceutical and agro businesses.

4. Brand Positioning: The demerger will enable different brand positioning for each legal entity, potentially strengthening their respective market presence.

Proposed Structure and Support

As part of the proposed reorganization, Natco Pharma may retain a small minority stake in the resulting agro company. This strategic decision is aimed at:

• Supporting the new entity with common services such as R&D and patents
• Providing assistance through Transitional Service Agreements (TSAs) at arm's length pricing

Next Steps

The board has authorized the management to:

1. Undertake a detailed evaluation of the proposed demerger
2. Suggest optimal capital and shareholding structures
3. Present findings to the Audit Committee and Board of Directors
4. Appoint necessary consultants, advisors, and intermediaries to progress the potential transaction

Timing and Disclosure

The board meeting where this decision was made took place on September 25, commencing at 10:00 a.m. and concluding at 10:35 a.m. Natco Pharma has committed to making appropriate disclosures in accordance with SEBI regulations and other applicable laws once the Board considers and approves the final structure of the transaction.

This strategic move by Natco Pharma reflects the company's commitment to optimizing its business structure and creating long-term value for its stakeholders. As the evaluation process unfolds, investors and industry observers will be keenly watching for further developments in this significant corporate restructuring initiative.